Information Library
Flexible outsourcing - Lower portfolio & investment risks
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
QUINTILES AND ALLERGAN ANNOUNCE CO-PROMOTION AGREEMENT
September 25, 2009 – Quintiles Transnational Corp. and Allergan, Inc. today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR®. -
Adrian McKemey, Ph.D.
March 25, 2009
Adrian leads the Product Development and Commercialization consulting practice at Quintiles Global Consulting. -
Jim Featherstone, Ph.D.
March 25, 2009
Jim joined Quintiles Consulting from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the UK, where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice. -
Jay Norman
March 24, 2009
President – Quintiles Consulting Jay brings 25 years of experience in the consulting industry and a strong track record of growth, most recently with Diamond Management and Technology Consultants, where he served as President and Chief Operating Officer. -
A New Gold Standard for Pricing
September 26, 2008
Dr. John Doyle, practice leader for market access at Quintiles Consulting, introduces the concept of a health economic balance sheet and evidence-based pricing for biopharmaceutical valuation. -
Differentiating Your Future Winners
September 19, 2008
Evidence-based Development and Smarter Sourcing by Jay Norman, president of Quintiles Consulting. -
Pressures and Opportunities
August 1, 2008
A Pharma TV interview with Ben Cons -
A New Gold Standard
May 1, 2008
May 2008 - John Doyle, DrPH, practice leader for market access at Quintiles Consulting, discusses the concept of a health economic balance sheet and the need for evidence-based pricing for biopharmaceutical valuation.
Page 1 of 1 (8 items)